{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T17:40:46Z","timestamp":1770399646110,"version":"3.49.0"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      Research on\n                      <jats:italic>SLCO1B1<\/jats:italic>\n                      polymorphisms and statin therapy in elderly patients is limited and controversial. This study explored the association of\n                      <jats:italic>SLCO1B1<\/jats:italic>\n                      c.521T&amp;gt;C and c.388A&amp;gt;G variants with coronary heart disease (CHD) risk, and evaluated the lipid-lowering efficacy and safety of standard-dose statins in subjects aged &amp;gt;75 years to provide evidence for geriatric clinical statin use.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A retrospective cohort study analyzed 6,146 individuals who were genotyped\n                      <jats:italic>SLCO1B1<\/jats:italic>\n                      variants c.521T&amp;gt;C and c.388A&amp;gt;G. 2318 participants were selected to evaluate the prevalence of diseases. 118 subjects (&amp;gt;75 years) were categorized into statin-treated (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200957) and control (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200961) groups. Lipid indices, liver function tests and muscle injury marker were measured by standard techniques.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The\n                      <jats:italic>SLCO1B1<\/jats:italic>\n                      c.521C allele was independently associated with increased CHD risk (odds ratio [OR]\u2009=\u20091.37, 95% CI:1.06\u20131.77,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.02). Statin therapy significantly reduced total cholesterol (TC: 3.70\u2009\u00b1\u20090.88 vs. 4.18\u2009\u00b1\u20090.84 mmol\/L,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.004) and low-density lipoprotein cholesterol (LDL-C: 1.88\u2009\u00b1\u20090.70 vs. 2.17\u2009\u00b1\u20090.61 mmol\/L,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.04) without elevating hepatic transaminases or creatine kinase (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;gt;\u20090.05). Carriers of the c.388A allele exhibited greater TC\/LDL-C reductions compared to c.388GG homozygotes (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;lt;\u20090.05), whereas the c.521T\u2009&amp;gt;\u2009C polymorphism showed no significant impact on therapeutic efficacy or safety outcomes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      The\n                      <jats:italic>SLCO1B<\/jats:italic>\n                      1 c.521C allele represents an independent genetic marker for CHD susceptibility in the southern Han Chinese population. In geriatric populations, standard-dose statin therapy maintains lipid-lowering efficacy and safety, unaffected by the\n                      <jats:italic>SLCO1B1<\/jats:italic>\n                      c.521T&amp;gt;C polymorphism. Our findings provide a genetic screening tool for the primary prevention of cardiovascular diseases and offer support for the efficacy and safety of statin-based lipid-lowering therapy in adults aged &amp;gt;75 years.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcvm.2026.1645446","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T06:36:36Z","timestamp":1770359796000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Analysis of the association between SLCO1B1 gene polymorphisms and coronary heart disease risk in southern Han Chinese population and statin responses in the elderly"],"prefix":"10.3389","volume":"13","author":[{"given":"Youmin","family":"Long","sequence":"first","affiliation":[{"name":"Department of Clinical Laboratory, Guangzhou First People's Hospital, Guangzhou Medical University","place":["Guangzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanling","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, The Affiliated Foshan Women and Children Hospital, Guangdong Medical University","place":["Foshan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuying","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, The Sixth Affiliated Hospital, Sun Yat-sen University","place":["Guangzhou, China"]},{"name":"Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University","place":["Guangzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangtie","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Guangzhou First People's Hospital, Guangzhou Medical University","place":["Guangzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guohao","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Guangzhou First People's Hospital, The Second Affiliated Hospital of South China University of Technology","place":["Guangzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuoran","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Radiology, Guangzhou Red Cross Hospital of Jinan University","place":["Guangzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiuxia","family":"Lei","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Guangzhou First People's Hospital, Guangzhou Medical University","place":["Guangzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jacc.2017.04.052","article-title":"Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015","volume":"70","author":"Roth","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/s0140-6736(18)31942-1","article-title":"Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials","volume":"393","author":"Armitage","year":"2019","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1016\/j.cjca.2016.01.003","article-title":"Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian consensus working group update (2016)","volume":"32","author":"Mancini","year":"2016","journal-title":"Can J Cardiol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"106246","DOI":"10.1016\/j.ejps.2022.106246","article-title":"Functional in vitro characterization of Slco1b1 variants and simulation of the clinical pharmacokinetic impact of impaired Oatp1b1 function","volume":"176","author":"Kiander","year":"2022","journal-title":"Eur J Pharm Sci"},{"key":"B5","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1002\/cpt.2337","article-title":"Effect of Slco1b1 T521c on statin-related myotoxicity with use of lovastatin and atorvastatin","volume":"110","author":"Lu","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"B6","doi-asserted-by":"publisher","first-page":"281","DOI":"10.2174\/1574884715666200827105612","article-title":"Slco1b1 gene polymorphisms (Rs2306283 and Rs4149056) and statin-induced myopathy in Jordanian diabetics","volume":"16","author":"Shahrure","year":"2021","journal-title":"Curr Rev Clin Exp Pharmacol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/s41397-021-00208-w","article-title":"A systematic review and meta-analysis of genotype-based and individualized data analysis of Slco1b1 gene and statin-induced myopathy","volume":"21","author":"Turongkaravee","year":"2021","journal-title":"Pharmacogenomics J"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e1046","DOI":"10.1161\/cir.0000000000000624","article-title":"2018 Aha\/Acc\/Aacvpr\/Aapa\/Abc\/Acpm\/Ada\/Ags\/Apha\/Aspc\/Nla\/Pcna guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1016\/s0140-6736(20)32332-1","article-title":"Efficacy and safety of lowering ldl cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials","volume":"396","author":"Gencer","year":"2020","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1002\/cpt.2557","article-title":"The clinical pharmacogenetics implementation consortium guideline for Slco1b1, Abcg2, and Cyp2c9 genotypes and statin-associated musculoskeletal symptoms","volume":"111","author":"Cooper-DeHoff","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"B11","doi-asserted-by":"publisher","first-page":"3516","DOI":"10.1093\/eurheartj\/ehz458","article-title":"Cardiovascular effect of discontinuing statins for primary prevention at the age of 75 years: a nationwide population-based cohort study in France","volume":"40","author":"Giral","year":"2019","journal-title":"Eur Heart J"},{"key":"B12","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/1471-2350-12-136","article-title":"Slco1b1 Rs4149056 polymorphism associated with statin-induced myopathy is differently distributed according to ethnicity in the Brazilian general population: Amerindians as a high risk ethnic group","volume":"12","author":"Santos","year":"2011","journal-title":"BMC Med Genet"},{"key":"B13","doi-asserted-by":"publisher","first-page":"i721","DOI":"10.1136\/bmj.i721","article-title":"Primary prevention and risk factor reduction in coronary heart disease mortality among working aged men and women in eastern Finland over 40 years: population based observational study","volume":"352","author":"Jousilahti","year":"2016","journal-title":"BMJ (Clin Res Ed)"},{"key":"B14","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1080\/09674845.2020.1785692","article-title":"Association between Slco1b1 polymorphism distribution frequency and blood lipid level in Chinese adults","volume":"78","author":"Mo","year":"2021","journal-title":"Br J Biomed Sci"},{"key":"B15","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1038\/sj.clpt.6100220","article-title":"Different effects of Slco1b1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin","volume":"82","author":"Pasanen","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European atherosclerosis society consensus panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur Heart J"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1001\/jama.2016.13985","article-title":"Association between lowering ldl-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis","volume":"316","author":"Silverman","year":"2016","journal-title":"JAMA"},{"key":"B18","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1001\/jama.2022.13044","article-title":"Statin use for the primary prevention of cardiovascular disease in adults: US preventive services task force recommendation statement","volume":"328","author":"Mangione","year":"2022","journal-title":"JAMA"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1190934","DOI":"10.3389\/fphar.2023.1190934","article-title":"2023 Chinese guideline for lipid management","volume":"14","author":"Li","year":"2023","journal-title":"Front Pharmacol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1001\/jama.2017.0382","article-title":"Use of statins in adults older than 75 years","volume":"317","author":"Stone","year":"2017","journal-title":"JAMA"},{"key":"B21","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.cger.2017.08.003","article-title":"Cardiovascular screening and primary prevention in older adults","volume":"34","author":"Orkaby","year":"2018","journal-title":"Clin Geriatr Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"19410","DOI":"10.1038\/s41598-019-55562-4","article-title":"Influence of Oatp1b1 and bcrp polymorphisms on the pharmacokinetics and pharmacodynamics of rosuvastatin in elderly and young Korean subjects","volume":"9","author":"Kim","year":"2019","journal-title":"Sci Rep"},{"key":"B23","doi-asserted-by":"publisher","first-page":"240s","DOI":"10.1177\/1076029618805863","article-title":"Associations of the Slco1b1 polymorphisms with hepatic function, baseline lipid levels, and lipid-lowering response to simvastatin in patients with hyperlipidemia","volume":"24","author":"Wu","year":"2018","journal-title":"Clin Appl Thromb Hemost"},{"key":"B24","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1097\/fpc.0000000000000412","article-title":"Association of Slco1b1 C.521t>C (Rs4149056) with discontinuation of atorvastatin due to statin-associated muscle symptoms","volume":"30","author":"Linskey","year":"2020","journal-title":"Pharmacogenet Genomics"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1346152","DOI":"10.3389\/fendo.2024.1346152","article-title":"The impact of Slco1b1 Rs4149056 on ldl-C target achievement after lipid lowering therapy optimization in men and women with familial hypercholesterolemia","volume":"15","author":"Bosco","year":"2024","journal-title":"Front Endocrinol (Lausanne)"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1645446\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T06:36:37Z","timestamp":1770359797000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1645446\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,6]]},"references-count":25,"alternative-id":["10.3389\/fcvm.2026.1645446"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1645446","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,6]]},"article-number":"1645446"}}